Plain-English translation of NCT06347705 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called 2141-V11, which works by waking up your immune system to find and kill cancer cells. Researchers want to see if combining this injection—given directly into the prostate tumor—with standard prostate cancer treatments can eliminate cancer more effectively and prevent any remaining cancer cells from coming back. The study will measure whether treatment completely clears the cancer or leaves only a tiny number of cancer cells that doctors can detect.
Standard treatments for prostate cancer work well for many men, but some tumors still return or progress despite treatment. This medication is designed to boost the body's own immune system to attack cancer cells more aggressively, potentially improving outcomes when combined with existing therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive a single injection of the medication directly into your prostate tumor at Memorial Sloan Kettering Cancer Center. Depending on whether you have intermediate-risk or high-risk disease, this injection will be given either before your scheduled prostate removal surgery or alongside standard hormone therapy. Your doctors will monitor you closely with blood tests and imaging to see how well the treatment works and check for any remaining cancer cells after therapy.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States